Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 46

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 46
---
: PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid
expenses and other current assets were comprised of the following:

SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS 

    September 30, 2025  
    December 31, 2024 
  
    Prepaid insurance 
    $504,325  
    $506,489 
  
    Prepaid research and development 
     900  
     150,000 
  
    Other prepaid expenses 
     108,129  
     175,088 
  
    Total prepaid expenses and other current assets 
    $613,354  
    $831,577 
  
    Prepaid
    expenses and other current assets 
    $613,354  
    $831,577 

NOTE
4: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts
payable and other current liabilities were comprised of the following:

SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES 

    September 30, 2025  
    December 31, 2024 
  
    Accounts payable 
    $707,420  
    $870,229 
  
    Accrued employee costs 
     43,389  
     1,371,498 
  
    Accrued professional fees 
     62,656  
     72,054 
  
    Accrued research and development 
     1,358,464  
     860,958 
  
    Accrued board fees 
     -  
     117,750 
  
    State franchise taxes payable 
     34,100  
     - 
  
    Other accrued expenses 
     19,610  
     17,228 
  
    Total accounts payable and other current liabilities 
    $2,225,639  
    $3,309,717 

    F-8

NOTE
5: STOCK-BASED COMPENSATION

The
Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the “2021 Plan”). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock
options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based
compensation. The 2021 Plan permits the Company’s board to